SS&C Technologies Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw record adjusted revenue, EBITDA, and EPS, with strong growth in GIDS, GlobeOp, and Intralinks. Full-year guidance was raised, capital returns prioritized, and AI-driven innovation and new product launches are expected to drive further momentum.
-
The event highlighted robust revenue growth, high margins, and strong cash flow driven by AI and automation, with no headcount increase. Strategic acquisitions, disciplined capital allocation, and expanding global platforms position the business for continued growth in 2026 and beyond.
-
The discussion highlighted disciplined capital allocation, margin expansion, and strong organic growth driven by technology and strategic acquisitions. AI and automation are central to operational efficiency, while high client retention and secure data practices reinforce competitive positioning.
Fiscal Year 2025
-
Record Q4 and full-year results featured strong revenue, margin expansion, and robust cash flow. Guidance for 2026 projects continued organic growth, margin improvement, and significant capital returns, with AI and recent acquisitions supporting long-term prospects.
-
Organic growth is driven by client expansion, international reach, and technology innovation, with key segments like GlobeOp, GIDS, and Healthcare performing strongly. Tokenization and AI are seen as both opportunities and challenges, while capital allocation favors M&A and buybacks.
-
Generative AI and automation are driving efficiency and growth, with a focus on high-value clients, global expansion, and robust risk management. Capital allocation now prioritizes buybacks and dividends, while disciplined acquisitions and innovation support long-term value.
-
Strong Q3 growth was driven by automation, AI, and expansion in alternatives and global markets. Strategic acquisitions like Calastone and Blue Prism enhance technology and cross-sell opportunities, while tailored solutions and disciplined capital allocation support continued momentum.
-
Record Q3 results with 7% adjusted revenue growth and 17.2% higher adjusted EPS, driven by strong GlobeOp and GIDS performance. Cash flow rose 22%, guidance for 2025 was raised, and recent acquisitions expand digital and international capabilities.
-
Investments in technology, international expansion, and automation are driving growth and operational efficiency. AI and Blue Prism are enhancing productivity and margins, while M&A remains opportunistic with a focus on accretive deals. International and alternatives businesses are key growth engines.
-
Q2 2025 saw record adjusted revenue and EBITDA, with strong organic growth in key segments and robust international performance. Guidance for 2025 was raised, and the Calastone acquisition is expected to be accretive. Continued investment in AI and technology supports future growth.
-
Mission-critical services drive stable demand and healthy pipelines, with private markets and technology-led innovation fueling growth. Margin expansion continues through automation, while new platforms and acquisitions support future opportunities.
-
A leading software and outsourcing provider for financial services and healthcare, the firm projects $6 billion in 2025 revenue, with strong recurring revenue, robust cash flow, and a focus on R&D and M&A. Growth is driven by product innovation, international expansion, and disciplined capital allocation.
-
Cloud-based solutions and integrated platforms drive growth, especially in alternatives and international markets. Pricing remains stable, with premium justified by solution breadth. Automation and AI enhance efficiency and innovation, while M&A and capital allocation strategies support expansion.
-
Q1 2025 saw 5.5% revenue growth and 8.3% higher adjusted EPS, with strong performance in GlobeOp, Wealth, and GIDS segments. Guidance for 2025 was raised, with organic growth expected to accelerate in H2, supported by new deals and international expansion.
-
A global provider of financial and healthcare technology is driving growth through increased R&D, tighter business integration, and disciplined M&A. Organic revenue growth is accelerating, with high retention and cross-selling as key strategies. GenAI and automation are enhancing efficiency and service quality.
-
The event highlighted record financial performance, accelerated organic growth, and the impact of strategic acquisitions and technology investments. Strong client relationships, disciplined capital allocation, and a focus on culture and innovation underpin continued expansion and new opportunities, especially in healthcare.
Fiscal Year 2024
-
Record Q4 and full year 2024 results driven by strong organic growth across all segments, with adjusted revenue up 8.4% and EPS up 25.4% year-over-year. 2025 guidance targets 5% organic growth, continued investment in automation, and major new client wins in Australia and healthcare.
-
Organic growth is accelerating across business segments, with strong momentum in Intralinks and stabilization in healthcare expected by 2025. Product innovation is driven by client feedback, and recent acquisitions like Battea are set to deliver revenue synergies. Retention remains high among complex clients, and capital allocation is focused on value-enhancing opportunities.
-
The conference highlighted transformational growth through acquisitions, advanced automation, and a focus on large, complex clients. Enhanced retention, cross-selling, and operational efficiency have driven organic growth and improved margins, while capital allocation now favors buybacks over debt paydown.
-
Leadership, R&D, and customer focus have improved business positioning, supporting growth in GIDS, wealth, and alternatives. Q4 guidance reflects normalization, with medium-term organic growth of 4–8% expected. Automation and M&A drive efficiency and expansion, with margin improvement targeted.
-
Record Q3 results with 7.3% adjusted revenue growth and 10.3% EPS increase, driven by strong performance in alternatives, GIDS, and WIT. Battea acquisition is accretive, and automation initiatives are boosting efficiency. Q4 guidance reflects tough comps but continued growth momentum.
-
Management outlined a strategy focused on platform integration, AI-driven innovation, and global expansion, supporting 4%-8% organic revenue growth and 38%-43% margins. Recurring revenues, disciplined capital allocation, and productivity gains from automation underpin strong cash flow and shareholder returns.
-
Record Q2 results featured 6.5% revenue growth, 17.6% higher adjusted EPS, and robust cash flow. Guidance for 2024 was raised, with strong performance in alternatives, GIDS, and wealth technology, and the largest-ever share buyback completed.
-
The organization has restructured its business into new verticals, focusing on efficiency and growth in areas like retirement, alternatives, and technology. Blue Prism has driven significant margin expansion, while healthcare is poised for growth through the DomaniRx partnership. Organic growth is prioritized, with ongoing portfolio optimization and disciplined cost management.
-
A leading financial software provider highlighted strong recurring revenue growth, high client retention, and a robust M&A track record. Margin expansion and cash flow growth are expected in 2024, supported by technology investments and operational efficiencies.